These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31302760)

  • 1. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
    Hari P; Khandelwal P; Smoyer WE
    Pediatr Nephrol; 2020 Sep; 35(9):1601-1619. PubMed ID: 31302760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.
    Hari P; Khandelwal P; Satpathy A; Hari S; Thergaonkar R; Lakshmy R; Sinha A; Bagga A
    Pediatr Nephrol; 2018 Dec; 33(12):2299-2309. PubMed ID: 30091061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
    Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
    Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld U
    Pediatr Nephrol; 1999 Jan; 13(1):77-84. PubMed ID: 10100296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
    Prescott WA; Streetman DA; Streetman DS
    Ann Pharmacother; 2004 Dec; 38(12):2105-14. PubMed ID: 15507504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current and future trends in the treatment of dyslipidemias].
    Vrablík M
    Vnitr Lek; 2019; 65(10):643-650. PubMed ID: 31906686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current guidelines for treatment of dyslipidemia in kidney diseases].
    Jędras M; Dylewska M
    Wiad Lek; 2014; 67(3):426-8. PubMed ID: 25782205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.